Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.

@article{Niccolini2015AlteredPE,
  title={Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.},
  author={Flavia Niccolini and Salman Haider and Tiago Reis Marques and N. Muhlert and Andri C. Tziortzi and Graham E. Searle and S Natesan and Paola Piccini and Shitij Kapur and Eugenii A. Rabiner and Roger N. Gunn and Sarah J Tabrizi and Marios Politis},
  journal={Brain : a journal of neurology},
  year={2015},
  volume={138 Pt 10},
  pages={
          3016-29
        }
}
There is an urgent need for early biomarkers and novel disease-modifying therapies in Huntington's disease. Huntington's disease pathology involves the toxic effect of mutant huntingtin primarily in striatal medium spiny neurons, which highly express phosphodiesterase 10A (PDE10A). PDE10A hydrolyses cAMP/cGMP signalling cascades, thus having a key role in the regulation of striatal output, and in promoting neuronal survival. PDE10A could be a key therapeutic target in Huntington's disease. Here… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 68 REFERENCES

Similar Papers

Loading similar papers…